Skip to main content
Erschienen in: Spektrum der Augenheilkunde 4/2013

01.08.2013 | original article

Intravitreal bevacizumab for pigment epithelial detachments in age-related macular degeneration

verfasst von: Victoria Hamelmann, MD, FEBO, Hans -Martin Helb, MD,FEBO, Carsten H. Meyer, MD, Frank G. Holz, MD, Nicole Eter, MD

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Summary

Background

To evaluate the efficacy and safety of intravitreal bevacizumab injections in patients with pigment epithelial detachments (PEDs) secondary to age-related macular degeneration (AMD).

Material and methods

In a retrospective interventional case series, 62 eyes of 61 patients were treated with 1.5 mg bevacizumab intravitreally. Baseline and follow-up visits included best-corrected visual acuity and optical coherence tomography (OCT) examinations. Follow-up visits were performed 1, 3, and 6 months after initial treatment. Morphological effects on PED were quantified by repetitively measuring the highest elevation on two perpendicular OCT cross-sections. If height of PED was increased by 50 microns, or intraretinal fluid appeared or increased, or visual acuity decreased more than 5 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, patients were reinjected.

Results

On OCT, PED decreased from 346 ± 148 µm at baseline to 241 ± 159 µm (p < 0.001) at 1 month, 227 ± 193 µm (p < 0.001) at 3 months, and 166 ± 170 µm (p < 0.001) at 6 months. Mean best corrected visual acuity (BCVA) increased from 49 ± 18 letters at baseline to 52 ± 21 letters (p = 0.062) at 1 month. However, 3 and 6 months after initial injection mean BCVA returned to baseline levels (3 months: 49 ± 19 letters, p = 0.518; 6 months: 49 ± 20 letters, p = 0.053). On average, patients received 2.5 injections during the observation period of 6 months. Except for one retinal pigment epithelial (RPE) tear no other ocular or systemic adverse events were noticed. Ocular inflammation was not found in any of the investigated patients.

Conclusions

The presented data demonstrate a therapeutic effect of intravitreal bevacizumab in patients with specific classes of pigment epithelial detachments secondary to AMD.
Literatur
1.
Zurück zum Zitat Poliner LS, Olk RJ, Burgess D, Gordon ME. Natural history of retinal pigment epithelial detachments in age-related macular degeneration. Ophthalmology. 1986;93(5):543–51.PubMed Poliner LS, Olk RJ, Burgess D, Gordon ME. Natural history of retinal pigment epithelial detachments in age-related macular degeneration. Ophthalmology. 1986;93(5):543–51.PubMed
2.
Zurück zum Zitat Meredith TA, Braley RE, Aaberg TM. Natural history of serous detachments of the retinal pigment epithelium. Am J Ophthalmol. 1979;88(4):643–51.PubMed Meredith TA, Braley RE, Aaberg TM. Natural history of serous detachments of the retinal pigment epithelium. Am J Ophthalmol. 1979;88(4):643–51.PubMed
3.
Zurück zum Zitat Elman MJ, Fine SL, Murphy RP, et al. The natural history of serous retinal pigment epithelium detachment in patients with age-related macular degeneration. Ophthalmology. 1986;93(2):224–30.PubMed Elman MJ, Fine SL, Murphy RP, et al. The natural history of serous retinal pigment epithelium detachment in patients with age-related macular degeneration. Ophthalmology. 1986;93(2):224–30.PubMed
4.
Zurück zum Zitat Verhoeff FH, Grossman HP. The pathogenesis of disciform degeneration of the macula. Trans Am Ophthalmol Soc. 1937;35:262–94.PubMed Verhoeff FH, Grossman HP. The pathogenesis of disciform degeneration of the macula. Trans Am Ophthalmol Soc. 1937;35:262–94.PubMed
5.
Zurück zum Zitat Murphy RP, Yeo JH, Green WR, Patz A. Dehiscences of the pigment epithelium. Trans Am Ophthalmol Soc. 1985;83:63–81.PubMed Murphy RP, Yeo JH, Green WR, Patz A. Dehiscences of the pigment epithelium. Trans Am Ophthalmol Soc. 1985;83:63–81.PubMed
6.
Zurück zum Zitat Green WR, McDonnell PJ, Yeo JH. Pathologic features of senile macular degeneration. Retina. 1985(2005);25(5 Suppl):615–27. Green WR, McDonnell PJ, Yeo JH. Pathologic features of senile macular degeneration. Retina. 1985(2005);25(5 Suppl):615–27.
7.
Zurück zum Zitat Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch’s membrane. A histochemical and morphologic study. Ophthalmology. 1990;97(2):171–8.PubMed Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch’s membrane. A histochemical and morphologic study. Ophthalmology. 1990;97(2):171–8.PubMed
8.
Zurück zum Zitat Bird AC, Marshall J. Retinal pigment epithelial detachments in the elderly. Trans Ophthalmol Soc U K. 1986;105(Pt 6):674–82.PubMed Bird AC, Marshall J. Retinal pigment epithelial detachments in the elderly. Trans Ophthalmol Soc U K. 1986;105(Pt 6):674–82.PubMed
9.
Zurück zum Zitat Gass JD. Serous retinal pigment epithelial detachment with a notch: a sign of occult choroidal neovascularization. Retina. 1984(2003);23(6 Suppl):205–20.CrossRef Gass JD. Serous retinal pigment epithelial detachment with a notch: a sign of occult choroidal neovascularization. Retina. 1984(2003);23(6 Suppl):205–20.CrossRef
10.
Zurück zum Zitat The Moorfields Macular Study Group. Retinal pigment epithelial detachments in the elderly. A controlled trial of argon laser photocoagulation. Br J Ophthalmol. 1982;66(1):1–16. The Moorfields Macular Study Group. Retinal pigment epithelial detachments in the elderly. A controlled trial of argon laser photocoagulation. Br J Ophthalmol. 1982;66(1):1–16.
11.
Zurück zum Zitat Pece A, Isola V, Vadala M, Calori G. Photodynamic therapy with verteporfin for choroidal neovascularization associated with retinal pigment epithelial detachment in age-related macular degeneration. Retina. 2007;27(3):342–8.PubMedCrossRef Pece A, Isola V, Vadala M, Calori G. Photodynamic therapy with verteporfin for choroidal neovascularization associated with retinal pigment epithelial detachment in age-related macular degeneration. Retina. 2007;27(3):342–8.PubMedCrossRef
12.
Zurück zum Zitat Axer-Siegel R, Ehrlich R, Avisar I, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic Surg Lasers Imaging. 2006;37(6):455–61.PubMed Axer-Siegel R, Ehrlich R, Avisar I, et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic Surg Lasers Imaging. 2006;37(6):455–61.PubMed
13.
Zurück zum Zitat Lommatzsch AP, Heimes B, Gutfleisch M, et al. Treatment of vascularized serous pigment epithelium detachment in AMD—observations after changing the intravitreal agent due to lack of response. Klin Monbl Augenheilkd. 2008;225(10):874–9.PubMedCrossRef Lommatzsch AP, Heimes B, Gutfleisch M, et al. Treatment of vascularized serous pigment epithelium detachment in AMD—observations after changing the intravitreal agent due to lack of response. Klin Monbl Augenheilkd. 2008;225(10):874–9.PubMedCrossRef
14.
Zurück zum Zitat Ruppenstein M, Ach T, Hoh A, Dithmar S. Effect of intravitreal bevacizumab on pigment epithelial detachment in occult choroidal neovascularization. Ophthalmologe. 2010;107(9):827–30.PubMedCrossRef Ruppenstein M, Ach T, Hoh A, Dithmar S. Effect of intravitreal bevacizumab on pigment epithelial detachment in occult choroidal neovascularization. Ophthalmologe. 2010;107(9):827–30.PubMedCrossRef
15.
Zurück zum Zitat Lommatzsch A, Heimes B, Gutfleisch M, et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond). 2009;23(12):2163–8.CrossRef Lommatzsch A, Heimes B, Gutfleisch M, et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond). 2009;23(12):2163–8.CrossRef
16.
Zurück zum Zitat Ach T, Hoeh AE, Ruppenstein M, et al. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina. 2010;30(9):1420–5.PubMedCrossRef Ach T, Hoeh AE, Ruppenstein M, et al. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina. 2010;30(9):1420–5.PubMedCrossRef
17.
Zurück zum Zitat Ritter M, Bolz M, Sacu S, et al. Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye (Lond). 2010;24(6):962–8.CrossRef Ritter M, Bolz M, Sacu S, et al. Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye (Lond). 2010;24(6):962–8.CrossRef
18.
Zurück zum Zitat Arias L. Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. Clin Ophthalmol. 2010;4:369–74.PubMedCrossRef Arias L. Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. Clin Ophthalmol. 2010;4:369–74.PubMedCrossRef
19.
Zurück zum Zitat Ladas ID, Kotsolis AI, Papakostas TD, et al. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina. 2007;27(7):891–6.PubMedCrossRef Ladas ID, Kotsolis AI, Papakostas TD, et al. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina. 2007;27(7):891–6.PubMedCrossRef
20.
Zurück zum Zitat Shima C, Gomi F, Sawa M, et al. One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247(7):899–906.PubMedCrossRef Shima C, Gomi F, Sawa M, et al. One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247(7):899–906.PubMedCrossRef
21.
Zurück zum Zitat el Matri L, Chebil A, Kort F, et al. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):779–84.PubMedCrossRef el Matri L, Chebil A, Kort F, et al. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):779–84.PubMedCrossRef
22.
Zurück zum Zitat Hajouli N, Hirsh A, Quintyn JC. Triple therapy for the treatment of choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. J Fr Ophtalmol. 2010;33(7):487–92.PubMedCrossRef Hajouli N, Hirsh A, Quintyn JC. Triple therapy for the treatment of choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. J Fr Ophtalmol. 2010;33(7):487–92.PubMedCrossRef
23.
Zurück zum Zitat Frimpong-Boateng A, Varde MA, Rufer F, et al. Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD. Ophthalmologe. 2008;105(7):661–8.PubMedCrossRef Frimpong-Boateng A, Varde MA, Rufer F, et al. Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD. Ophthalmologe. 2008;105(7):661–8.PubMedCrossRef
24.
Zurück zum Zitat Subramanyam A, Phatak S, Chudgar D. Large retinal pigment epithelium rip following serial intravitreal injection of avastin in a large fibrovascular pigment epithelial detachment. Indian J Ophthalmol. 2007;55(6):483–6.PubMed Subramanyam A, Phatak S, Chudgar D. Large retinal pigment epithelium rip following serial intravitreal injection of avastin in a large fibrovascular pigment epithelial detachment. Indian J Ophthalmol. 2007;55(6):483–6.PubMed
25.
Zurück zum Zitat Chan CK, Lin SG. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol. 2007;17(4):674–6.PubMed Chan CK, Lin SG. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol. 2007;17(4):674–6.PubMed
26.
Zurück zum Zitat Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina. 2007;27(4):445–50.PubMedCrossRef Chen E, Kaiser RS, Vander JF. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina. 2007;27(4):445–50.PubMedCrossRef
27.
Zurück zum Zitat Chan CK, Abraham P, Meyer CH, et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina. 2009;30(2):203–11.CrossRef Chan CK, Abraham P, Meyer CH, et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina. 2009;30(2):203–11.CrossRef
28.
Zurück zum Zitat Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol. 1985;69(6):397–403.PubMedCrossRef Casswell AG, Kohen D, Bird AC. Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol. 1985;69(6):397–403.PubMedCrossRef
29.
Zurück zum Zitat Pauleikhoff D, Loffert D, Spital G, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol. 2002;240(7):533–8.PubMedCrossRef Pauleikhoff D, Loffert D, Spital G, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol. 2002;240(7):533–8.PubMedCrossRef
30.
Zurück zum Zitat Schuman JS, Fujimoto JG, Puliafito CA. Optical coherence tomography of ocular diseases. Slack Incorporated; 2004/5. Schuman JS, Fujimoto JG, Puliafito CA. Optical coherence tomography of ocular diseases. Slack Incorporated; 2004/5.
31.
Zurück zum Zitat Eter N, Bindewald A, Roth F, Holz FG. OCT in age-related macular degeneration. Findings, usage in clinical routine, and assessment of treatment outcome. Ophthalmologe. 2004;101(8):794–803.PubMed Eter N, Bindewald A, Roth F, Holz FG. OCT in age-related macular degeneration. Findings, usage in clinical routine, and assessment of treatment outcome. Ophthalmologe. 2004;101(8):794–803.PubMed
32.
Zurück zum Zitat Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32(6):375–413.PubMedCrossRef Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32(6):375–413.PubMedCrossRef
33.
Zurück zum Zitat Gass JDM. Stereoscopic atlas of macular disease: diagnosis and management. St. Louis:Mosby; 1997. Gass JDM. Stereoscopic atlas of macular disease: diagnosis and management. St. Louis:Mosby; 1997.
34.
Zurück zum Zitat Gass JD. Retinal pigment epithelial rip during krypton red laser photocoagulation. Am J Ophthalmol. 1984;98(6):700–6.PubMed Gass JD. Retinal pigment epithelial rip during krypton red laser photocoagulation. Am J Ophthalmol. 1984;98(6):700–6.PubMed
35.
Zurück zum Zitat Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment–TAP and VIP report No. 2. Arch Ophthalmol. 2003;121(9):1253–68.PubMedCrossRef Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment–TAP and VIP report No. 2. Arch Ophthalmol. 2003;121(9):1253–68.PubMedCrossRef
36.
Zurück zum Zitat Schaal KB, Engler C, Schutt F, et al. Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD. Ophthalmologe. 2008;105(6):538–43.PubMedCrossRef Schaal KB, Engler C, Schutt F, et al. Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD. Ophthalmologe. 2008;105(6):538–43.PubMedCrossRef
37.
Zurück zum Zitat Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(10):1868–75.PubMedCrossRef Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(10):1868–75.PubMedCrossRef
38.
Zurück zum Zitat Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am. 2006;19(3):361–72.PubMed Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am. 2006;19(3):361–72.PubMed
39.
Zurück zum Zitat Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245(1):68–73.PubMedCrossRef Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245(1):68–73.PubMedCrossRef
40.
Zurück zum Zitat Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144(4):627–37.PubMedCrossRef Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144(4):627–37.PubMedCrossRef
41.
Zurück zum Zitat Cohen SY, Korobelnik JF, Tadayoni R, et al. [Monitoring anti-VEGF drugs for treatment of exudative AMD]. J Fr Ophtalmol. 2007;30(4):330–4.PubMedCrossRef Cohen SY, Korobelnik JF, Tadayoni R, et al. [Monitoring anti-VEGF drugs for treatment of exudative AMD]. J Fr Ophtalmol. 2007;30(4):330–4.PubMedCrossRef
42.
Zurück zum Zitat Helb HM, Issa PC, Fleckenstein M, et al. Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution, spectral-domain optical coherence tomography. Acta Ophthalmol. 2010;88(8):842–9.PubMedCrossRef Helb HM, Issa PC, Fleckenstein M, et al. Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution, spectral-domain optical coherence tomography. Acta Ophthalmol. 2010;88(8):842–9.PubMedCrossRef
43.
Zurück zum Zitat Meyer CH, Helb HM, Eter N. [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series]. Ophthalmologe. 2008;105(2):125–38,140–22.PubMedCrossRef Meyer CH, Helb HM, Eter N. [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series]. Ophthalmologe. 2008;105(2):125–38,140–22.PubMedCrossRef
44.
Zurück zum Zitat Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363–72.e365.PubMedCrossRef Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363–72.e365.PubMedCrossRef
45.
Zurück zum Zitat Smretschnig E, Krebs I, Moussa S, et al. Cirrus OCT versus Spectralis OCT: differences in segmentation in fibrovascular pigment epithelial detachment. Graefes Arch Clin Exp Ophthalmol. 2010;248(12):1693–8.PubMedCrossRef Smretschnig E, Krebs I, Moussa S, et al. Cirrus OCT versus Spectralis OCT: differences in segmentation in fibrovascular pigment epithelial detachment. Graefes Arch Clin Exp Ophthalmol. 2010;248(12):1693–8.PubMedCrossRef
46.
Zurück zum Zitat Mylonas G, Ahlers C, Malamos P, et al. Comparison of retinal thickness measurements and segmentation performance of four different spectral and time domain OCT devices in neovascular age-related macular degeneration. Br J Ophthalmol. 2009;93(11):1453–60.PubMedCrossRef Mylonas G, Ahlers C, Malamos P, et al. Comparison of retinal thickness measurements and segmentation performance of four different spectral and time domain OCT devices in neovascular age-related macular degeneration. Br J Ophthalmol. 2009;93(11):1453–60.PubMedCrossRef
47.
Zurück zum Zitat Levy J, Shneck M, Rosen S, et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol. 2009;29(5):349–57.PubMedCrossRef Levy J, Shneck M, Rosen S, et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol. 2009;29(5):349–57.PubMedCrossRef
48.
Zurück zum Zitat Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol. 2008;146(1):91–5.PubMedCrossRef Melamud A, Stinnett S, Fekrat S. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Am J Ophthalmol. 2008;146(1):91–5.PubMedCrossRef
49.
Zurück zum Zitat Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27(4):439–44.PubMedCrossRef Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27(4):439–44.PubMedCrossRef
50.
Zurück zum Zitat Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(7):3115–20.PubMedCrossRef Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(7):3115–20.PubMedCrossRef
51.
Zurück zum Zitat Moutray T, Alarbi M, Mahon G, et al. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularization. Br J Ophthalmol. 2008;92(3):361–4.PubMedCrossRef Moutray T, Alarbi M, Mahon G, et al. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularization. Br J Ophthalmol. 2008;92(3):361–4.PubMedCrossRef
52.
Zurück zum Zitat Ting TD, M Oh, Cox TA, et al. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol. 2002;120(6):731–7.PubMedCrossRef Ting TD, M Oh, Cox TA, et al. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol. 2002;120(6):731–7.PubMedCrossRef
53.
Zurück zum Zitat Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. Retina. 2005;25(6):691–6.PubMedCrossRef Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. Retina. 2005;25(6):691–6.PubMedCrossRef
54.
Zurück zum Zitat Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 355(14):1432–44. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 355(14):1432–44.
55.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.PubMedCrossRef Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.PubMedCrossRef
56.
Zurück zum Zitat Meyer CH, Mennel S, Schmidt JC, Kroll P. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularization secondary to age related macular degeneration. Br J Ophthalmol. 2006;90(9):1207–8.PubMedCrossRef Meyer CH, Mennel S, Schmidt JC, Kroll P. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularization secondary to age related macular degeneration. Br J Ophthalmol. 2006;90(9):1207–8.PubMedCrossRef
57.
Zurück zum Zitat Pece A, Introini U, Bottoni F, Brancato R. Acute retinal pigment epithelial tear after photodynamic therapy. Retina. 2001;21(6):661–5.PubMedCrossRef Pece A, Introini U, Bottoni F, Brancato R. Acute retinal pigment epithelial tear after photodynamic therapy. Retina. 2001;21(6):661–5.PubMedCrossRef
58.
Zurück zum Zitat Michels S, Aue A, Simader C, et al. Retinal pigment epithelium tears following verteporfin therapy combined with intravitreal triamcinolone. Am J Ophthalmol. 2006;141(2):396–8.PubMedCrossRef Michels S, Aue A, Simader C, et al. Retinal pigment epithelium tears following verteporfin therapy combined with intravitreal triamcinolone. Am J Ophthalmol. 2006;141(2):396–8.PubMedCrossRef
59.
Zurück zum Zitat Yeo JH, Marcus S, Murphy RP. Retinal pigment epithelial tears. Patterns and prognosis. Ophthalmology. 1988;95(1):8–13.PubMed Yeo JH, Marcus S, Murphy RP. Retinal pigment epithelial tears. Patterns and prognosis. Ophthalmology. 1988;95(1):8–13.PubMed
60.
Zurück zum Zitat Dhalla MS, Blinder KJ, Tewari A, et al. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol. 2006;141(4):752–4.PubMedCrossRef Dhalla MS, Blinder KJ, Tewari A, et al. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol. 2006;141(4):752–4.PubMedCrossRef
61.
Zurück zum Zitat Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(4):623.e1. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(4):623.e1.
62.
Zurück zum Zitat Hoskin A, Bird AC, Sehmi K. Tears of detached retinal pigment epithelium. Br J Ophthalmol. 1981;65(6):417–22.PubMedCrossRef Hoskin A, Bird AC, Sehmi K. Tears of detached retinal pigment epithelium. Br J Ophthalmol. 1981;65(6):417–22.PubMedCrossRef
63.
Zurück zum Zitat Ronan SM, Yoganathan P, Chien FY, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina. 2007;27(5):535–40.PubMedCrossRef Ronan SM, Yoganathan P, Chien FY, et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina. 2007;27(5):535–40.PubMedCrossRef
64.
Zurück zum Zitat Weinberger AW, Thiel M, Mohammadi B, et al. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol. 2007;144(2):294–6.PubMedCrossRef Weinberger AW, Thiel M, Mohammadi B, et al. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Ophthalmol. 2007;144(2):294–6.PubMedCrossRef
65.
Zurück zum Zitat Kook D, Wolf A, Neubauer AS, et al. Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress. Ophthalmologe. 2008;105(2):158–64.PubMedCrossRef Kook D, Wolf A, Neubauer AS, et al. Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress. Ophthalmologe. 2008;105(2):158–64.PubMedCrossRef
Metadaten
Titel
Intravitreal bevacizumab for pigment epithelial detachments in age-related macular degeneration
verfasst von
Victoria Hamelmann, MD, FEBO
Hans -Martin Helb, MD,FEBO
Carsten H. Meyer, MD
Frank G. Holz, MD
Nicole Eter, MD
Publikationsdatum
01.08.2013
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 4/2013
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-013-0177-2

Weitere Artikel der Ausgabe 4/2013

Spektrum der Augenheilkunde 4/2013 Zur Ausgabe

editorial

Editorial